Selected research
Market Structure
Global CD133 Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global CD133 Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for CD133 Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of CD133 Antibody include Thermo Fisher Scientific, Boster Biological Technology, United States Biological, Proteintech, NSJ Bioreagents, Miltenyi Biotec, HUABIO, GeneTex and Cell Signaling Technology, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global CD133 Antibody market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of CD133 Antibody and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents CD133 Antibody revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the CD133 Antibody market size, projected growth trends, production technologies, key applications, and end-use industries.
CD133 Antibody Segment by Company
Thermo Fisher Scientific
Boster Biological Technology
United States Biological
Proteintech
NSJ Bioreagents
Miltenyi Biotec
HUABIO
GeneTex
Cell Signaling Technology
Bioss
BioLegend
Beckman Coulter
Abcam
CD133 Antibody Segment by Type
Polyclonal
Monoclonal
CD133 Antibody Segment by Application
Western Blot
Enzyme Linked Immunosorbent Assay
Immunocytochemistry
Immunohistochemistry
Others
CD133 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD133 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of CD133 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD133 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of CD133 Antibody in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD133 Antibody industry.
Chapter 3: Detailed analysis of CD133 Antibody companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, CD133 Antibodyrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Polyclonal
- Monoclonal
Applications
- Western Blot
- Enzyme Linked Immunosorbent Assay
- Immunocytochemistry
- Immunohistochemistry
- Others
Companies covered
- Thermo Fisher Scientific
- Boster Biological Technology
- United States Biological
- Proteintech
- NSJ Bioreagents
- Miltenyi Biotec
- HUABIO
- GeneTex
- Cell Signaling Technology
- Bioss
- BioLegend
- Beckman Coulter
- Abcam
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global CD133 Antibody Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Polyclonal
- 1.2.3 Monoclonal
- 1.3 Market Analysis by Application
- 1.3.1 Global CD133 Antibody Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Western Blot
- 1.3.3 Enzyme Linked Immunosorbent Assay
- 1.3.4 Immunocytochemistry
- 1.3.5 Immunohistochemistry
- 1.3.6 Others
- 1.4 Global Market Growth Prospects
- 1.5 Global CD133 Antibody Growth Trends by Region
- 1.5.1 Global CD133 Antibody Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 CD133 Antibody Market Size by Region (2021-2026)
- 1.5.3 CD133 Antibody Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global CD133 Antibody Market Dynamics
- 2.1 CD133 Antibody Industry Trends
- 2.2 CD133 Antibody Industry Drivers
- 2.3 CD133 Antibody Industry Opportunities and Challenges
- 2.4 CD133 Antibody Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global CD133 Antibody Revenue by Company (2021-2026)
- 3.2 Global CD133 Antibody Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global CD133 Antibody Key Company Head office and Area Served
- 3.4 Global CD133 Antibody Company, Product Type & Application
- 3.5 Global CD133 Antibody Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global CD133 Antibody Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 CD133 Antibody Players Market Share by Revenue in 2025
- 3.6.3 2025 CD133 Antibody Tier 1, Tier 2, and Tier 3
4 CD133 Antibody Market by Type
- 4.1 Global CD133 Antibody Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global CD133 Antibody Market Size by Type (2021-2032)
- 4.3 Global CD133 Antibody Market Size Share by Type (2021-2032)
5 CD133 Antibody Market by Application
- 5.1 Global CD133 Antibody Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global CD133 Antibody Market Size by Application (2021-2032)
- 5.3 Global CD133 Antibody Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Thermo Fisher Scientific
- 6.1.1 Thermo Fisher Scientific Company Information
- 6.1.2 Thermo Fisher Scientific Business Overview
- 6.1.3 Thermo Fisher Scientific CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Thermo Fisher Scientific CD133 Antibody Product Portfolio
- 6.1.5 Thermo Fisher Scientific Recent Developments
- 6.2 Boster Biological Technology
- 6.2.1 Boster Biological Technology Company Information
- 6.2.2 Boster Biological Technology Business Overview
- 6.2.3 Boster Biological Technology CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Boster Biological Technology CD133 Antibody Product Portfolio
- 6.2.5 Boster Biological Technology Recent Developments
- 6.3 United States Biological
- 6.3.1 United States Biological Company Information
- 6.3.2 United States Biological Business Overview
- 6.3.3 United States Biological CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 United States Biological CD133 Antibody Product Portfolio
- 6.3.5 United States Biological Recent Developments
- 6.4 Proteintech
- 6.4.1 Proteintech Company Information
- 6.4.2 Proteintech Business Overview
- 6.4.3 Proteintech CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Proteintech CD133 Antibody Product Portfolio
- 6.4.5 Proteintech Recent Developments
- 6.5 NSJ Bioreagents
- 6.5.1 NSJ Bioreagents Company Information
- 6.5.2 NSJ Bioreagents Business Overview
- 6.5.3 NSJ Bioreagents CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 NSJ Bioreagents CD133 Antibody Product Portfolio
- 6.5.5 NSJ Bioreagents Recent Developments
- 6.6 Miltenyi Biotec
- 6.6.1 Miltenyi Biotec Company Information
- 6.6.2 Miltenyi Biotec Business Overview
- 6.6.3 Miltenyi Biotec CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Miltenyi Biotec CD133 Antibody Product Portfolio
- 6.6.5 Miltenyi Biotec Recent Developments
- 6.7 HUABIO
- 6.7.1 HUABIO Company Information
- 6.7.2 HUABIO Business Overview
- 6.7.3 HUABIO CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 HUABIO CD133 Antibody Product Portfolio
- 6.7.5 HUABIO Recent Developments
- 6.8 GeneTex
- 6.8.1 GeneTex Company Information
- 6.8.2 GeneTex Business Overview
- 6.8.3 GeneTex CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 GeneTex CD133 Antibody Product Portfolio
- 6.8.5 GeneTex Recent Developments
- 6.9 Cell Signaling Technology
- 6.9.1 Cell Signaling Technology Company Information
- 6.9.2 Cell Signaling Technology Business Overview
- 6.9.3 Cell Signaling Technology CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Cell Signaling Technology CD133 Antibody Product Portfolio
- 6.9.5 Cell Signaling Technology Recent Developments
- 6.10 Bioss
- 6.10.1 Bioss Company Information
- 6.10.2 Bioss Business Overview
- 6.10.3 Bioss CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Bioss CD133 Antibody Product Portfolio
- 6.10.5 Bioss Recent Developments
- 6.11 BioLegend
- 6.11.1 BioLegend Company Information
- 6.11.2 BioLegend Business Overview
- 6.11.3 BioLegend CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 BioLegend CD133 Antibody Product Portfolio
- 6.11.5 BioLegend Recent Developments
- 6.12 Beckman Coulter
- 6.12.1 Beckman Coulter Company Information
- 6.12.2 Beckman Coulter Business Overview
- 6.12.3 Beckman Coulter CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Beckman Coulter CD133 Antibody Product Portfolio
- 6.12.5 Beckman Coulter Recent Developments
- 6.13 Abcam
- 6.13.1 Abcam Company Information
- 6.13.2 Abcam Business Overview
- 6.13.3 Abcam CD133 Antibody Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Abcam CD133 Antibody Product Portfolio
- 6.13.5 Abcam Recent Developments
7 North America
- 7.1 North America CD133 Antibody Market Size (2021-2032)
- 7.2 North America CD133 Antibody Market Size by Type
- 7.2.1 North America CD133 Antibody Market Size by Type (2021-2026)
- 7.2.2 North America CD133 Antibody Market Size by Type (2027-2032)
- 7.2.3 North America CD133 Antibody Market Share by Type (2021-2032)
- 7.3 North America CD133 Antibody Market Size by Application
- 7.3.1 North America CD133 Antibody Market Size by Application (2021-2026)
- 7.3.2 North America CD133 Antibody Market Size by Application (2027-2032)
- 7.3.3 North America CD133 Antibody Market Share by Application (2021-2032)
- 7.4 North America CD133 Antibody Market Size by Country
- 7.4.1 North America CD133 Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America CD133 Antibody Market Size by Country (2021-2026)
- 7.4.3 North America CD133 Antibody Market Size by Country (2027-2032)
- 7.4.4 North America CD133 Antibody Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe CD133 Antibody Market Size (2021-2032)
- 8.2 Europe CD133 Antibody Market Size by Type
- 8.2.1 Europe CD133 Antibody Market Size by Type (2021-2026)
- 8.2.2 Europe CD133 Antibody Market Size by Type (2027-2032)
- 8.2.3 Europe CD133 Antibody Market Share by Type (2021-2032)
- 8.3 Europe CD133 Antibody Market Size by Application
- 8.3.1 Europe CD133 Antibody Market Size by Application (2021-2026)
- 8.3.2 Europe CD133 Antibody Market Size by Application (2027-2032)
- 8.3.3 Europe CD133 Antibody Market Share by Application (2021-2032)
- 8.4 Europe CD133 Antibody Market Size by Country
- 8.4.1 Europe CD133 Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe CD133 Antibody Market Size by Country (2021-2026)
- 8.4.3 Europe CD133 Antibody Market Size by Country (2027-2032)
- 8.4.4 Europe CD133 Antibody Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China CD133 Antibody Market Size (2021-2032)
- 9.2 China CD133 Antibody Market Size by Type
- 9.2.1 China CD133 Antibody Market Size by Type (2021-2026)
- 9.2.2 China CD133 Antibody Market Size by Type (2027-2032)
- 9.2.3 China CD133 Antibody Market Share by Type (2021-2032)
- 9.3 China CD133 Antibody Market Size by Application
- 9.3.1 China CD133 Antibody Market Size by Application (2021-2026)
- 9.3.2 China CD133 Antibody Market Size by Application (2027-2032)
- 9.3.3 China CD133 Antibody Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia CD133 Antibody Market Size (2021-2032)
- 10.2 Asia CD133 Antibody Market Size by Type
- 10.2.1 Asia CD133 Antibody Market Size by Type (2021-2026)
- 10.2.2 Asia CD133 Antibody Market Size by Type (2027-2032)
- 10.2.3 Asia CD133 Antibody Market Share by Type (2021-2032)
- 10.3 Asia CD133 Antibody Market Size by Application
- 10.3.1 Asia CD133 Antibody Market Size by Application (2021-2026)
- 10.3.2 Asia CD133 Antibody Market Size by Application (2027-2032)
- 10.3.3 Asia CD133 Antibody Market Share by Application (2021-2032)
- 10.4 Asia CD133 Antibody Market Size by Country
- 10.4.1 Asia CD133 Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia CD133 Antibody Market Size by Country (2021-2026)
- 10.4.3 Asia CD133 Antibody Market Size by Country (2027-2032)
- 10.4.4 Asia CD133 Antibody Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa CD133 Antibody Market Size (2021-2032)
- 11.2 South America, Middle East & Africa CD133 Antibody Market Size by Type
- 11.2.1 South America, Middle East & Africa CD133 Antibody Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa CD133 Antibody Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa CD133 Antibody Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa CD133 Antibody Market Size by Application
- 11.3.1 South America, Middle East & Africa CD133 Antibody Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa CD133 Antibody Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa CD133 Antibody Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa CD133 Antibody Market Size by Country
- 11.4.1 South America, Middle East & Africa CD133 Antibody Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa CD133 Antibody Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa CD133 Antibody Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa CD133 Antibody Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst